Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

DexCom, Inc. (DXCM)

Surgical & Medical Instruments & Apparatus

https://www.dexcom.com

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

6340 SEQUENCE DRIVE
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/14/2005

Market Cap

29,850,154,230

Shares Outstanding

386,370,000

Weighted SO

381,673,935

Total Employees

N/A

Upcoming Earnings

07/25/2024

Beta

1.1590

Last Div

0.0000

Range

62.34-142.0

Chg

2.1300

Avg Vol

5046491

Mkt Cap

29850154230

Exch

NASDAQ

Country

US

Phone

858 200 0200

DCF Diff

33.0695

DCF

39.2905

Div Yield

0.0000

P/S

7.5862

EV Multiple

34.6021

P/FV

12.2156

Div Yield %

0.0000

P/E

44.5890

PEG

1.7669

Payout

0.0000

Current Ratio

2.8152

Quick Ratio

2.4841

Cash Ratio

0.5453

DSO

92.6414

DIO

141.9624

Op Cycle

234.6039

DPO

76.4202

CCC

158.1836

Gross Margin

0.6274

Op Margin

0.1732

Pretax Margin

0.2051

Net Margin

0.1695

Eff Tax Rate

0.1735

ROA

0.0981

ROE

0.2958

ROCE

0.1342

NI/EBT

0.8265

EBT/EBIT

1.1840

EBIT/Rev

0.1732

Debt Ratio

0.3617

D/E

1.0103

LT Debt/Cap

0.5004

Total Debt/Cap

0.5026

Int Coverage

47.3264

CF/Debt

0.3624

Equity Multi

2.7931

Rec Turnover

3.9399

Pay Turnover

4.7762

Inv Turnover

2.5711

FA Turnover

3.1370

Asset Turnover

0.5787

OCF/Share

2.2330

FCF/Share

1.6671

Cash/Share

7.8174

OCF/Sales

0.2265

FCF/OCF

0.7466

CF Coverage

0.3624

ST Coverage

41.2685

CapEx Coverage

3.9460

Div&CapEx Cov

3.9460

P/BV

12.2156

P/B

12.2156

P/S

7.5862

P/E

44.5890

P/FCF

44.8537

P/OCF

33.3592

P/CF

33.3592

PEG

1.7669

P/S

7.5862

EV Multiple

34.6021

P/FV

12.2156

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 09, 22:30 Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders Benzinga Apr 04, 19:47 Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry The Motley Fool Feb 14, 00:02 DexCom: Revenue Up, EPS Misses Mark The Motley Fool Nov 24, 15:15 2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Invest The Motley Fool Oct 25, 21:53 Why DexCom Stock Flopped on Friday GlobeNewswire Inc. Oct 20, 21:54 DXCM DEADLINE: RLF, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important October 21 Deadline in Securities Class Action – DXCM GlobeNewswire Inc. Oct 13, 16:05 ROSEN, LEADING TRIAL ATTORNEYS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – DXCM The Motley Fool Oct 12, 15:40 2 Magnificent Stocks to Buy That Are Near 52-Week Lows GlobeNewswire Inc. Oct 12, 15:15 DexCom, Inc. (DXCM) Investors: October 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc. Oct 11, 00:36 ROSEN, LEADING INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – DXCM GlobeNewswire Inc. Oct 04, 00:50 ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM GlobeNewswire Inc. Sep 30, 22:48 ROSEN, NATIONAL TRIAL LAWYERS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM GlobeNewswire Inc. Sep 27, 00:32 DXCM ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against DexCom, Inc. GlobeNewswire Inc. Sep 26, 00:42 SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom GlobeNewswire Inc. Sep 25, 00:03 ROSEN, A RANKED AND LEADING FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM GlobeNewswire Inc. Sep 10, 01:19 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM GlobeNewswire Inc. Sep 05, 22:32 DXCM Lawsuit Reminder: Robbins LLP Encourages DexCom Inc. Stockholders to Seek Counsel for Class Action Lawsuit GlobeNewswire Inc. Sep 02, 00:15 ROSEN, LEADING TRIAL ATTORNEYS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM GlobeNewswire Inc. Aug 30, 00:43 DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom GlobeNewswire Inc. Aug 28, 23:27 ROSEN, A TOP RANKED LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

Revenue Product Segmentation

a